Tony McLoughlin (Sligo-Leitrim, Fine Gael)
Link to this: Individually | In context | Oireachtas source

447. To ask the Minister for Health his plans for further dialogue with industry on finding solutions for access for persons to new medicines; if speed of access and funding growth for new medicines will be ensured in view of his commitments at the recent meeting of an association (details supplied); and if he will make a statement on the matter. [50530/17]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

Medicines play a vital role in improving the overall health of Irish patients. Securing affordable access to existing and new medicines in a timely manner is a key objective of the Irish Health Service. However, the challenge is delivering on this objective in an affordable and sustainable way in line with the resources allocated by the Dáil and the relevant legislative provisions. Expenditure on medicines represents one of the largest areas of expenditure across the health service and will continue to grow in the years ahead as our health service continues to meet the needs of our citizens

My Department and the HSE are engaging in a number of initiatives which have led and will continue to lead to better access to medicines for patients, value for the taxpayer and the cost- effective provision of medicines in Ireland. Key initiatives include reference and generic substitution, under the Health (Pricing and Supply of Medical Goods) Act 2013, the four year Framework Agreement on the Supply and Pricing of Medicines with IPHA, the Medicines Management Programme and National Drugs Management Programme within the HSE, and the development of a National Biosimilar Medicines Policy. Ireland is also participating in a number of discussions amongst EU Member states to explore possible areas for collaboration including potential joint price negotiations and procurement.

However, access to medicines is not solely a funding issue. A significant barrier to accessing new medicines is the price being sought by some manufacturers for their products. The solution to increased access is multifaceted and is not simply a matter of allocating more funding for medicines at the expense of other health or public services. The health service must continue to seek better value and lower costs for both existing and new treatments.

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. This Act gives full statutory powers to the HSE to assess and make decision on the reimbursement of medicines, taking account of expert opinion as appropriate. There is also an increased level of engagement and commercial negotiations between the HSE and manufacturers in an effort to reduce the price to affordable levels. So while this process is resource intensive, it is clear that as a result of such a robust and scientific process, Ireland is paying significantly less for medicines and the ability to invest is enhanced.

In my recent speech at the IPHA Annual Meeting and Dinner, I highlighted the need for innovative solutions to accessing new medicines. To this end, my Department will continue to consider how improvements can be made to the current system, and will, as part of this work, engage with key stakeholders in 2018 in this regard.